Woulgan listed on UK Drug Tariff from 1 December 2017

Woulgan’s listing on UK Drug Tariff has been brought forward by one month from January 1st 2018 to December 1st 2017 with a reimbursement price of 20 GBP.

-We can now actively market the product in both community and in hospital settings, promoting Woulgan with healthcare personnel to try and get their own experience with the product. Individuals’ clinical experiences are a fundamental step in building Woulgan sales because healthcare personnel expect to have positive results for themselves before recommending to use a product regularly, says CEO Christian Jørgensen.